

A comprehensive compilation of hard-to-find news/company announcements of the last month, monthly stock price changes and the latest quarter's financial performance of companies in Japan's Life Science sector.

[Current Month's News](#) | [Monthly Stock Movement](#) | [Gainers & Decliners](#) | [Latest Quarter Financial Performance](#)

Table of Contents

Company News: By Company Name	1
Company News: By Industry	9
Company News: By News Category	17
Stock Analysis - Top Gainers and Decliners in Japan Life Science Sector	27
Financial Performance of Japan Life Science Sector	28

SECTION A: NEWS

Companies Covered in News:

3 D Matrix Ltd | A&D Company Ltd | Acucela Inc. | AnGes MG, Inc. | ARKRAY Inc. | Asahi Kasei Corporation | Astellas Pharma Inc. | Chugai Pharmaceutical Co. Ltd. | Daiichi Sankyo Company Limited | Eisai Co. Limited | Fuji Pharma Company Limited | Fujifilm Holdings Corporation | Healios K.K. | Hitachi Aloka Medical, Ltd. | Japan Life Company Limited | Kissei Pharmaceutical Company Limited | Kyowa Hakko Kirin Co. Ltd | Maruho Co., Ltd. | Nippon Shinyaku Co., Ltd. | Ohara Inc | Olympus Corporation | OncoTherapy Science, Inc. | Ono Pharmaceutical Co., Ltd. | Otsuka Pharmaceutical Co., Ltd. | Shimadzu Corporation | Sysmex Corporation | Taisho Pharmaceutical Holdings Co., Ltd. | Takeda Pharmaceutical Company Ltd | Teva Pharmaceutical Industries Ltd. | Topcon Corporation | Torii Pharmaceutical Co., Ltd. | Toshiba Medical Systems Corporation | Yamato Scientific Co. Ltd. |

Company News: By Company Name

[3 D Matrix Ltd \(www\)](#), (Ticker: 7777)

3-D Matrix announces Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand - The company said that its subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Thailand has been granted by the regulatory body, Food and Drug Administration Thailand (FDA Thailand). [More...](#) (January 25, 2016)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic

Goods Administration (TGA). [More...](#) (January 22, 2016)

Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT - In regards to a self-assembling peptide technology that the company has exclusive licensing rights from the Massachusetts Institute of Technology, the company announced that a patent filed by MIT, the licensor, related to bone / cartilage regeneration and skin regeneration fields in which developments are in progress was granted in Canada. [More...](#) (January 05, 2016)

A&D Company Ltd ([www](#)), (Ticker: 7745)

A&D Company, Limited and AtCor Medical to consider central blood pressure measurement equipment business collaboration - The company will consider business collaboration with aortic pressure measurement equipment pioneer AtCor Medical. [More...](#) (January 12, 2016)

Acucela Inc. ([www](#)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

AnGes MG, Inc. ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

ARKRAY Inc. ([www](#))

Establishing an integrated manufacturing system and enhancing global competitiveness Completion ceremony held for instrument factory and distribution center in the Philippines - Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September 2011. [More...](#) (January 21, 2016)

Asahi Kasei Corporation ([www](#)), (Ticker: 3407)

Asahi Kasei Construction Materials receives administrative dispositions in accordance with Construction Business Act - Asahi Kasei Construction Materials Corp., a subsidiary of the company received the following administrative dispositions from the Kanto Regional Development Bureau of the Ministry of Land, Infrastructure, Transport and Tourism, in accordance with Paragraphs 1 and 3 of Article 28 and Paragraph 1 of Article 41 of the Construction Business Act. [More...](#) (January 13, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February 9, 2016. [More...](#) (January 22, 2016)

Astellas hooks up with NuMedii to continue drug repurposing deal drive - The company has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan (\$AGN) among its clients. [More...](#) (January 15, 2016)

Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet - The U.S. arm of the company and U.S.-listed Medivation said that enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC). [More...](#) (January 14, 2016)

Extension of agreement on Telmisartan (Micardis® family) - Nippon Boehringer Ingelheim Co., Ltd. and the company have decided to extend the agreement pertaining to the sale and co-promotion in Japan for telmisartan (Micardis® family). The term of the agreement, which runs to December 31, 2016, will be extended to March 31, 2018. [More...](#) (January 07, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 23, 2016)

Chugai and Novartis Pharma to terminate co-marketing agreement of Aromatase Inhibitor "Femara® Tablets 2.5 mg," a treatment for breast cancer after menopause - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor "Femara® tablets 2.5 mg" (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016. [More...](#) (January 06, 2016)

Daiichi Sankyo Company Limited ([www](#)), (Ticker: 4568)

Daiichi Sankyo announces results of phase 3 international joint trial (RApsody) of Investigational Etanercept Biosimilar - The company announced that they have achieved major objectives in the Phase 3 international joint trial (RApsody) of CHS-0214, an investigational etanercept (genetical recombination) biosimilar*1 in rheumatoid arthritis (RA) under development with the U.S. company, Coherus BioSciences, Inc. (hereinafter, Coherus). [More...](#) (January 12, 2016)

Daiichi Sankyo announces change in Corporate Officer's responsibilities - The company announced a change in the responsibilities of one of its Corporate Officers effective February 1, 2016. [More...](#) (January 08, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA)

has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Eisai submits new application in Europe for in-house developed anticancer agent lenvatinib seeking approval for indication covering renal cell carcinoma - The company announced that its European regional headquarters Eisai Europe Ltd. has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma. [More...](#) (January 12, 2016)

Development of a treatment for Eumycetoma, one of the world's most neglected diseases - The company has signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to jointly develop Eisai's azole-class antifungal drug E1224 (fosravuconazole) as a potential new treatment for eumycetoma. [More...](#) (January 08, 2016)

Fuji Pharma Company Limited ([www](#)), (Ticker: 4554)

Fuji Pharma signs license agreement for Darbepoetin Alfa, An erythropoiesis-stimulating agents - The company announced that it has signed a license agreement with Chong Kun Dang Pharmaceutical Corp. Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of Darbepoetin Alfa Biosimilar. [More...](#) (January 05, 2016)

Fujifilm Holdings Corporation ([www](#)), (Ticker: 4554)

Fujifilm to bid for Toshiba's medical equipment unit - The company plans to participate in the upcoming bidding for Toshiba Corp.'s fully owned medical equipment unit, it has been learned. [More...](#) (January 16, 2016)

Healios K.K. ([www](#)), (Ticker: 4593)

Announcement of collaboration between Healios and Athersys for regenerative medicine products marketed in Japan using MultiStem® cell therapy and fund borrowing by Healios - The company and Athersys, Inc. have announced a partnership and license agreement for the development of regenerative medicine products that will be developed and marketed in Japan by Healios, making use of Athersys' proprietary, patented stem cell product, MultiStem® cell therapy. [More...](#) (January 08, 2016)

Hitachi Aloka Medical, Ltd. ([www](#))

Hitachi announces changes in the method of the reorganization of Hitachi Medical and Hitachi Aloka Medical and the execution of absorption-type company split agreement - Hitachi Ltd, Hitachi Medical Corporation and the company announced that a decision has been made regarding the absorption type merger of Hitachi Medical and the company by Hitachi and the establishment of a manufacturing subsidiary as part of efforts to strengthen the health care business. [More...](#) (January 13, 2016)

Japan Life Company Limited ([www](#)), (Ticker: 7575)

Announcement of regulatory approval for the atrial septal defect (ASD) occluder "Figulla Flex II" - Japan Lifeline announced that, on January 5, the company had received regulatory approval for the ASD Occluder "Figulla Flex II" manufactured by Occlutech (Switzerland). The sales launch is scheduled on

February 1, 2016. [More...](#) (January 12, 2016)

Kissei Pharmaceutical Company Limited ([www](#)), (Ticker: 4547)

Announcement of the launch of Urief® OD Tab. (orally disintegrating tablets) for the treatment of dysuria associated with benign prostatic hyperplasia in Japan - Kissei Pharmaceutical Co., Ltd. announced that they will launch Urief® OD Tab. 2mg and Urief® OD Tab. 4mg (generic name: silodosin, hereinafter referred to as the “drug”) for the treatment of dysuria associated with benign prostatic hyperplasia on January 18. [More...](#) (January 15, 2016)

Kyowa Hakko Kirin Co. Ltd ([www](#)), (Ticker: 4151)

Kyowa Hakko Kirin entered an agreement with Sandoz for exclusive marketing rights of Rituximab biosimilar in Japan - Kyowa Hakko Kirin Co., Ltd. announced that it entered into an agreement with Sandoz KK, a Novartis company, for exclusive marketing rights to Sandoz' biosimilar Rituximab in Japan. [More...](#) (January 25, 2016)

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Nippon Shinyaku Co., Ltd. ([www](#)), (Ticker: 4516)

Nippon Shinyaku submits NDA to MHLW for Selexipag for treatment of pulmonary arterial hypertension. - Nippon Shinyaku Co., Ltd. announced the submission of the New Drug Application (NDA) for selexipag which was originally discovered and synthesized by Nippon Shinyaku Co., Ltd. and was jointly developed in Japan with Actelion Pharmaceuticals Japan Ltd., to the Ministry of Health, Labor and Welfare (MHLW) for the treatment of pulmonary arterial hypertension (PAH). [More...](#) (January 07, 2016)

Ohara Inc ([www](#)), (Ticker: 5218)

Ultra-Low expansion glass ceramics which was adopted for the world's largest telescope~ production upgrade of CLEARCERAM™-Z - Ohara Incorporation has built another large furnace for ultra low expansion glass ceramics, CLEARCERAM™-Z, for stable supply and further increase in demand. [More...](#) (January 13, 2016)

Olympus Corporation ([www](#))

Olympus receives 510(k) clearance for TJF-Q180V Duodenoscope - Olympus announced that FDA has cleared the 510(k) for the TJF-Q180V duodenoscope with modifications to the device design and labeling. The duodenoscope is a flexible gastrointestinal endoscope used in procedures such as endoscopic retrograde cholangiopancreatography (ERCP), which is most commonly performed to diagnose and treat conditions in the pancreas, bile duct and gallbladder. [More...](#) (January 15, 2016)

OncoTherapy Science, Inc. ([www](#)), (Ticker: 4564)

The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA - OncoTherapy Science, Inc. announces that we will conduct Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA). [More...](#) (January 25, 2016)

MELK inhibitor, OTS167, Phase I clinical study commencement in Australia - OncoTherapy Science, Inc announces that the Human Research Ethics Committee (HRECs) at the trial site in Australia has approved the commencement of Phase I clinical study of MELK inhibitor, OTS167. [More...](#) (January 05, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

ONO submits manufacturing and marketing approval application in Japan for “Etelcalcetide Hydrochloride” (ONO-5163), a calcimimetic agent, for secondary hyperparathyroidism in patients on hemodialysis - ONO PHARMACEUTICAL CO., LTD. announced the submission of Manufacturing and Marketing Approval Application in Japan for “etelcalcetide hydrochloride” (ONO-5163) , a calcimimetic agent, to seek an indication for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. [More...](#) (January 14, 2016)

Otsuka Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4578)

Otsuka Pharmaceutical enters into comprehensive health promotion partnership with Iwate Prefecture - Otsuka Pharmaceutical has entered into a Comprehensive health promotion partnership with Iwate Prefecture as part of the Healthy Iwate 21 Plan to promote healthy longevity and improve the quality of life for prefectural citizens. [More...](#) (January 13, 2016)

Otsuka and ARIAD announce new drug application for ponatinib submitted in Japan for the treatment of refractory leukemia - Ponatinib (generic name) is a tyrosine kinase inhibitor discovered by ARIAD Pharmaceuticals in the United States. The New Drug Application (NDA) for ponatinib was filed in Japan for the first time as a novel oral treatment for chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). [More...](#) (January 08, 2016)

Shimadzu Corporation ([www](#)), (Ticker: 7701)

Shimadzu releases the Xslicer SMX-6000 microfocus X-Ray inspection system the first system from Shimadzu to integrate inclined fluoroscopy and CT imaging into a single package - Shimadzu Corporation announces the release of the Xslicer SMX-6000 microfocus X-ray inspection system for non-destructive inspections. This is the first Shimadzu system to include inclined fluoroscopy and CT imaging functionalities in a single package and which is capable of obtaining cross-sectional images immediately after inclined fluoroscopy. [More...](#) (January 07, 2016)

Sysmex Corporation ([www](#)), (Ticker: 6869)

Medicaroid Corporation's US subsidiary commences operations in Silicon Valley - Medicaroid Corporation, a joint venture between Sysmex Corporation and Kawasaki Heavy Industries, Ltd., has

established a subsidiary in the United States, Medicaroid, Inc., which commenced operations in January 2016. [More...](#) (January 13, 2016)

Sysmex enters business alliance agreement with Eiken Chemical Co., Ltd., involving the urine chemistry testing business in overseas markets - Sysmex Corporation has entered a business alliance with Eiken Chemical Co. Ltd. involving the urine chemistry testing business in overseas markets. Going forward, the two companies aim to collaborate to become frontrunners in the urinalysis field. [More...](#) (January 08, 2016)

Sysmex launches the UC-3500 Fully-Automated Urine Chemistry Analyzer, its First Product in the Field of Urine Qualitative Analysis in Overseas Markets - Sysmex Corporation is launching the UC-3500 fully-automated urine chemistry analyzer, its first urine qualitative analyzer under its own brand to overseas markets, based on a business alliance with Eiken Chemical Co. Ltd. [More...](#) (January 08, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape - Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda

Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100 Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Takeda and enGene establish strategic alliance to develop novel therapeutics for gastrointestinal diseases - Takeda Pharmaceutical Company Ltd. and enGene, Inc. announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene's "Gene Pill" gene delivery platform. [More...](#) (January 12, 2016)

Takeda, NsGene collaborate to develop cell encapsulation therapies for Parkinson's disease - Takeda Pharmaceutical Company Limited and NsGene, Inc. announced a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson's disease. The partnership will focus on the delivery of recombinant Glial Cell Line-Derived Neurotrophic Factor (GDNF) to affected brain regions by way of implanted, encapsulated cell therapy devices. [More...](#) (January 09, 2016)

Takeda acquires U.S. biologics manufacturing facility - Takeda Pharmaceutical Company Limited announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc. Takeda intends to use the facility primarily for the manufacture of Entyvio® and other biologic products, allowing the company to maximize global efficiencies and further enhance the product's supply chain flexibility. [More...](#) (January 06, 2016)

Takeda and Enterome enter strategic drug discovery collaboration focused on microbiome targets across multiple gastrointestinal disorders - Takeda Pharmaceutical Company Ltd. and Enterome Bioscience SA announced that they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases and motility disorders. [More...](#) (January 06, 2016)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials - Teva Pharmaceutical Industries Ltd. and Active Biotech announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients. [More...](#) (January 04, 2016)

Topcon Corporation ([www](#)), (Ticker: 7732)

Topcon invests in Viasys VDC - Topcon Positioning Group announces that it has acquired a significant share of holdings in Viasys VDC, based in Espoo, Finland. [More...](#) (January 12, 2016)

Torii Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4551)

Aiming to contribute to psoriasis treatment in Japan, contract signed for strategic co-promotion for Ixekizumab, humanized anti-interleukin-17 monoclonal antibody - Eli Lilly Japan K.K. and Torii Pharmaceutical Co., Ltd. announced that the two companies signed a strategic sales collaboration contract in the area of dermatology in Japan for a humanized anti-interleukin-17 monoclonal antibody "Ixekizumab [recombinant], hereinafter called the Ixekizumab" that Eli Lilly Japan is developing and has filed an application for the manufacture and sale approval for the treatment of Moderate-to-Severe Plaque Psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis last year in Japan. [More...](#)

(January 08, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" - Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Toshiba Medical Systems Corp sets up JV subsidiary in Malaysia - JAPAN'S Toshiba Medical Systems Corporation (TMSC) has established Toshiba Medical Systems Malaysia Sdn Bhd as a joint venture corporation with TMSC's distributor in Malaysia, Abex Medical System Sdn Bhd. [More...](#) (January 12, 2016)

Sony and Fujifilm Holdings mulling bids for Toshiba Medical Systems - Sony and Fujifilm Holdings are considering joining the fray to acquire a Toshiba medical equipment subsidiary, raising the prospect of a bidding war for a growth business. [More...](#) (January 06, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

[Top](#)

Company News: By Industry

Biotech

Acucela Inc. ([www](#)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

Kissei Pharmaceutical Company Limited ([www](#)), (Ticker: 4547)

Announcement of the launch of Urief® OD Tab. (orally disintegrating tablets) for the treatment of dysuria associated with benign prostatic hyperplasia in Japan - Kissei Pharmaceutical Co., Ltd. announced that they will launch Urief® OD Tab. 2mg and Urief® OD Tab. 4mg (generic name: silodosin, hereinafter referred to as the "drug") for the treatment of dysuria associated with benign prostatic hyperplasia on January 18. [More...](#) (January 15, 2016)

OncoTherapy Science, Inc. ([www](#)), (Ticker: 4564)

The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA - OncoTherapy Science, Inc. announces that we will conduct Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA). [More...](#) (January 25, 2016)

MELK inhibitor, OTS167, Phase I clinical study commencement in Australia - OncoTherapy Science, Inc announces that the Human Research Ethics Committee (HRECs) at the trial site in Australia has approved the commencement of Phase I clinical study of MELK inhibitor, OTS167. [More...](#) (January 05, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

Medical Dev/Tech/Supp

3 D Matrix Ltd ([www](#)), (Ticker: 7777)

3-D Matrix announces Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand - The company said that its subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Thailand has been granted by the regulatory body, Food and Drug Administration Thailand (FDA Thailand). [More...](#) (January 25, 2016)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT - In regards to a self-assembling peptide technology that the company has exclusive licensing rights from the Massachusetts Institute of Technology, the company announced that a patent filed by MIT, the licensor, related to bone / cartilage regeneration and skin regeneration fields in which developments are in progress was granted in Canada. [More...](#) (January 05, 2016)

A&D Company Ltd ([www](#)), (Ticker: 7745)

A&D Company, Limited and AtCor Medical to consider central blood pressure measurement equipment business collaboration - The company will consider business collaboration with aortic pressure measurement equipment pioneer AtCor Medical. [More...](#) (January 12, 2016)

ARKRAY Inc. ([www](#))

Establishing an integrated manufacturing system and enhancing global competitiveness Completion ceremony held for instrument factory and distribution center in the Philippines - Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September

2011. [More...](#) (January 21, 2016)

Hitachi Aloka Medical, Ltd. ([www](#))

Hitachi announces changes in the method of the reorganization of Hitachi Medical and Hitachi Aloka Medical and the execution of absorption-type company split agreement - Hitachi Ltd, Hitachi Medical Corporation and the company announced that a decision has been made regarding the absorption type merger of Hitachi Medical and the company by Hitachi and the establishment of a manufacturing subsidiary as part of efforts to strengthen the health care business. [More...](#) (January 13, 2016)

Japan Life Company Limited ([www](#)), (Ticker: 7575)

Announcement of regulatory approval for the atrial septal defect (ASD) occluder "Figulla Flex II" - Japan Lifeline announced that, on January 5, the company had received regulatory approval for the ASD Occluder "Figulla Flex II" manufactured by Occlutech (Switzerland). The sales launch is scheduled on February 1, 2016. [More...](#) (January 12, 2016)

Ohara Inc ([www](#)), (Ticker: 5218)

Ultra-Low expansion glass ceramics which was adopted for the world's largest telescope-production upgrade of CLEARCERAM™-Z - Ohara Incorporation has built another large furnace for ultra low expansion glass ceramics, CLEARCERAM™-Z, for stable supply and further increase in demand. [More...](#) (January 13, 2016)

Olympus Corporation ([www](#))

Olympus receives 510(k) clearance for TJF-Q180V Duodenoscope - Olympus announced that FDA has cleared the 510(k) for the TJF-Q180V duodenoscope with modifications to the device design and labeling. The duodenoscope is a flexible gastrointestinal endoscope used in procedures such as endoscopic retrograde cholangiopancreatography (ERCP), which is most commonly performed to diagnose and treat conditions in the pancreas, bile duct and gallbladder. [More...](#) (January 15, 2016)

Shimadzu Corporation ([www](#)), (Ticker: 7701)

Shimadzu releases the Xslicer SMX-6000 microfocus X-Ray inspection system the first system from Shimadzu to integrate inclined fluoroscopy and CT imaging into a single package - Shimadzu Corporation announces the release of the Xslicer SMX-6000 microfocus X-ray inspection system for non-destructive inspections. This is the first Shimadzu system to include inclined fluoroscopy and CT imaging functionalities in a single package and which is capable of obtaining cross-sectional images immediately after inclined fluoroscopy. [More...](#) (January 07, 2016)

Sysmex Corporation ([www](#)), (Ticker: 6869)

Medicaroid Corporation's US subsidiary commences operations in Silicon Valley - Medicaroid Corporation, a joint venture between Sysmex Corporation and Kawasaki Heavy Industries, Ltd., has established a subsidiary in the United States, Medicaroid, Inc., which commenced operations in January 2016. [More...](#) (January 13, 2016)

Sysmex enters business alliance agreement with Eiken Chemical Co., Ltd., involving the urine chemistry testing business in overseas markets - Sysmex Corporation has entered a business alliance with Eiken Chemical Co. Ltd. involving the urine chemistry testing business in overseas markets. Going forward, the two companies aim to collaborate to become frontrunners in the urinalysis field.

[More...](#) (January 08, 2016)

Sysmex launches the UC-3500 Fully-Automated Urine Chemistry Analyzer, its First Product in the Field of Urine Qualitative Analysis in Overseas Markets - Sysmex Corporation is launching the UC-3500 fully-automated urine chemistry analyzer, its first urine qualitative analyzer under its own brand to overseas markets, based on a business alliance with Eiken Chemical Co. Ltd. [More...](#) (January 08, 2016)

Topcon Corporation ([www](#)), (Ticker: 7732)

Topcon invests in Viasys VDC - Topcon Positioning Group announces that it has acquired a significant share of holdings in Viasys VDC, based in Espoo, Finland. [More...](#) (January 12, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" -

Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Toshiba Medical Systems Corp sets up JV subsidiary in Malaysia - JAPAN'S Toshiba Medical Systems Corporation (TMSC) has established Toshiba Medical Systems Malaysia Sdn Bhd as a joint venture corporation with TMSC's distributor in Malaysia, Abex Medical System Sdn Bhd. [More...](#) (January 12, 2016)

Sony and Fujifilm Holdings mulling bids for Toshiba Medical Systems - Sony and Fujifilm Holdings are considering joining the fray to acquire a Toshiba medical equipment subsidiary, raising the prospect of a bidding war for a growth business. [More...](#) (January 06, 2016)

Pharmaceuticals

AnGes MG, Inc. ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

Asahi Kasei Corporation ([www](#)), (Ticker: 3407)

Asahi Kasei Construction Materials receives administrative dispositions in accordance with Construction Business Act - Asahi Kasei Construction Materials Corp., a subsidiary of the company received the following administrative dispositions from the Kanto Regional Development Bureau of the Ministry of Land, Infrastructure, Transport and Tourism, in accordance with Paragraphs 1 and 3 of Article 28 and Paragraph 1 of Article 41 of the Construction Business Act. [More...](#) (January 13, 2016)

Astellas Pharma Inc. (www), (Ticker: 4503)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February 9, 2016. [More...](#) (January 22, 2016)

Astellas hooks up with NuMedii to continue drug repurposing deal drive - The company has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan (\$AGN) among its clients. [More...](#) (January 15, 2016)

Astellas, Medivation report successful enzalutamide mCRPC PhII data in Lancet - The U.S. arm of the company and U.S.-listed Medivation said that enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC). [More...](#) (January 14, 2016)

Extension of agreement on Telmisartan (Micardis® family) - Nippon Boehringer Ingelheim Co., Ltd. and the company have decided to extend the agreement pertaining to the sale and co-promotion in Japan for telmisartan (Micardis® family). The term of the agreement, which runs to December 31, 2016, will be extended to March 31, 2018. [More...](#) (January 07, 2016)

Chugai Pharmaceutical Co. Ltd. (www), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 23, 2016)

Chugai and Novartis Pharma to terminate co-marketing agreement of Aromatase Inhibitor "Femara® Tablets 2.5 mg," a treatment for breast cancer after menopause - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor "Femara® tablets 2.5 mg" (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016. [More...](#) (January 06, 2016)

Daiichi Sankyo Company Limited (www), (Ticker: 4568)

Daiichi Sankyo announces results of phase 3 international joint trial (RApsody) of Investigational Etanercept Biosimilar - The company announced that they have achieved major objectives in the Phase 3 international joint trial (RApsody) of CHS-0214, an investigational etanercept (genetical recombination) biosimilar*1 in rheumatoid arthritis (RA) under development with the U.S. company, Coherus BioSciences, Inc. (hereinafter, Coherus). [More...](#) (January 12, 2016)

Daiichi Sankyo announces change in Corporate Officer's responsibilities - The company announced a change in the responsibilities of one of its Corporate Officers effective February 1, 2016. [More...](#)

(January 08, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Eisai submits new application in Europe for in-house developed anticancer agent lenvatinib seeking approval for indication covering renal cell carcinoma - The company announced that its European regional headquarters Eisai Europe Ltd. has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma. [More...](#) (January 12, 2016)

Development of a treatment for Eumycetoma, one of the world's most neglected diseases - The company has signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to jointly develop Eisai's azole-class antifungal drug E1224 (fosravuconazole) as a potential new treatment for eumycetoma. [More...](#) (January 08, 2016)

Fuji Pharma Company Limited ([www](#)), (Ticker: 4554)

Fuji Pharma signs license agreement for Darbepoetin Alfa, An erythropoiesis-stimulating agents - The company announced that it has signed a license agreement with Chong Kun Dang Pharmaceutical Corp. Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of Darbepoetin Alfa Biosimilar. [More...](#) (January 05, 2016)

Fujifilm Holdings Corporation ([www](#)), (Ticker: 4554)

Fujifilm to bid for Toshiba's medical equipment unit - The company plans to participate in the upcoming bidding for Toshiba Corp.'s fully owned medical equipment unit, it has been learned. [More...](#) (January 16, 2016)

Healios K.K. ([www](#)), (Ticker: 4593)

Announcement of collaboration between Healios and Athersys for regenerative medicine products marketed in Japan using MultiStem® cell therapy and fund borrowing by Healios - The company and Athersys, Inc. have announced a partnership and license agreement for the development of regenerative medicine products that will be developed and marketed in Japan by Healios, making use of Athersys' proprietary, patented stem cell product, MultiStem® cell therapy. [More...](#) (January 08, 2016)

Kyowa Hakko Kirin Co. Ltd ([www](#)), (Ticker: 4151)

Kyowa Hakko Kirin entered an agreement with Sandoz for exclusive marketing rights of Rituximab biosimilar in Japan - Kyowa Hakko Kirin Co., Ltd. announced that it entered into an agreement with Sandoz KK, a Novartis company, for exclusive marketing rights to Sandoz' biosimilar Rituximab in Japan. [More...](#) (January 25, 2016)

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Nippon Shinyaku Co., Ltd. ([www](#)), (Ticker: 4516)

Nippon Shinyaku submits NDA to MHLW for Selexipag for treatment of pulmonary arterial hypertension. - Nippon Shinyaku Co., Ltd. announced the submission of the New Drug Application (NDA) for selexipag which was originally discovered and synthesized by Nippon Shinyaku Co., Ltd. and was jointly developed in Japan with Actelion Pharmaceuticals Japan Ltd., to the Ministry of Health, Labor and Welfare (MHLW) for the treatment of pulmonary arterial hypertension (PAH). [More...](#) (January 07, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

ONO submits manufacturing and marketing approval application in Japan for “Etelcalcetide Hydrochloride” (ONO-5163), a calcimimetic agent, for secondary hyperparathyroidism in patients on hemodialysis - ONO PHARMACEUTICAL CO., LTD. announced the submission of Manufacturing and Marketing Approval Application in Japan for “etelcalcetide hydrochloride” (ONO-5163), a calcimimetic agent, to seek an indication for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. [More...](#) (January 14, 2016)

Otsuka Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4578)

Otsuka Pharmaceutical enters into comprehensive health promotion partnership with Iwate Prefecture - Otsuka Pharmaceutical has entered into a Comprehensive health promotion partnership with Iwate Prefecture as part of the Healthy Iwate 21 Plan to promote healthy longevity and improve the quality of life for prefectural citizens. [More...](#) (January 13, 2016)

Otsuka and ARIAD announce new drug application for ponatinib submitted in Japan for the treatment of refractory leukemia - Ponatinib (generic name) is a tyrosine kinase inhibitor discovered by ARIAD Pharmaceuticals in the United States. The New Drug Application (NDA) for ponatinib was filed in Japan for the first time as a novel oral treatment for chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). [More...](#) (January 08, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan “Bonviva® Tablet” - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQQA® Tape - Taisho Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical

Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Takeda Pharmaceutical Company Ltd ([www](http://www.takeda.com)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) - Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100 Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Takeda and enGene establish strategic alliance to develop novel therapeutics for gastrointestinal diseases - Takeda Pharmaceutical Company Ltd. and enGene, Inc. announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene's "Gene Pill" gene delivery platform. [More...](#) (January 12, 2016)

Takeda, NsGene collaborate to develop cell encapsulation therapies for Parkinson's disease - Takeda Pharmaceutical Company Limited and NsGene, Inc. announced a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson's disease. The partnership will focus on the delivery of recombinant Glial Cell Line-Derived Neurotrophic Factor (GDNF) to affected brain regions by way of implanted, encapsulated cell therapy devices. [More...](#) (January 09, 2016)

Takeda acquires U.S. biologics manufacturing facility - Takeda Pharmaceutical Company Limited announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc. Takeda intends to use the facility primarily for the manufacture of Entyvio® and other biologic products, allowing the company to maximize global efficiencies and further enhance the product's supply chain flexibility. [More...](#) (January 06, 2016)

Takeda and Enterome enter strategic drug discovery collaboration focused on microbiome targets across multiple gastrointestinal disorders - Takeda Pharmaceutical Company Ltd. and Enterome Bioscience SA announced that they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in

gastrointestinal disorders, including inflammatory bowel diseases and motility disorders. [More...](#) (January 06, 2016)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials - Teva Pharmaceutical Industries Ltd. and Active Biotech announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients. [More...](#) (January 04, 2016)

Torii Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4551)

Aiming to contribute to psoriasis treatment in Japan, contract signed for strategic co-promotion for Ixekizumab, humanized anti-interleukin-17 monoclonal antibody - Eli Lilly Japan K.K. and Torii Pharmaceutical Co., Ltd. announced that the two companies signed a strategic sales collaboration contract in the area of dermatology in Japan for a humanized anti-interleukin-17 monoclonal antibody "Ixekizumab [recombinant], hereinafter called the Ixekizumab" that Eli Lilly Japan is developing and has filed an application for the manufacture and sale approval for the treatment of Moderate-to-Severe Plaque Psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis last year in Japan. [More...](#) (January 08, 2016)

[Top](#)

Company News: By News Category

Awards/ Achievements

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda recognized as one of the global 100 Most Sustainable Corporations - Takeda Pharmaceuticals Company Limited is proud to be named by Corporate Knights to the 2016 Global 100 Most Sustainable Corporations in the World Index. [More...](#) (January 21, 2016)

Board of Directors

Daiichi Sankyo Company Limited ([www](#)), (Ticker: 4568)

Daiichi Sankyo announces change in Corporate Officer's responsibilities - The company announced a change in the responsibilities of one of its Corporate Officers effective February 1, 2016. [More...](#) (January 08, 2016)

Changes in Shareholding

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas extends tender offer to acquire all outstanding shares of Ocata Therapeutics - Astellas is committed to transaction, acquisition of Ocata is a strategic priority - The company and Ocata

Therapeutics, Inc. announced that Astellas has extended, through its indirect wholly-owned subsidiary Laurel Acquisition Inc., the offering period of the tender offer to purchase all issued and outstanding shares of common stock of Ocata for a price of USD8.50 per share, net to the holder in cash on February 9, 2016. [More...](#) (January 22, 2016)

Contracts/Deals

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas hooks up with NuMedii to continue drug repurposing deal drive - The company has signed its second tech-enabled drug repurposing deal in as many months. The latest deal connects Astellas to NuMedii, a digital drug discovery shop cofounded by Atul Butte that lists Allergan (\$AGN) among its clients. [More...](#) (January 15, 2016)

Extension of agreement on Telmisartan (Micardis® family) - Nippon Boehringer Ingelheim Co., Ltd. and the company have decided to extend the agreement pertaining to the sale and co-promotion in Japan for telmisartan (Micardis® family). The term of the agreement, which runs to December 31, 2016, will be extended to March 31, 2018. [More...](#) (January 07, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai and Novartis Pharma to terminate co-marketing agreement of Aromatase Inhibitor "Femara® Tablets 2.5 mg," a treatment for breast cancer after menopause - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai and Novartis Pharma K.K. have agreed to terminate the agreement regarding co-marketing of aromatase inhibitor "Femara® tablets 2.5 mg" (generic name: letrozole, hereafter Femara®), a treatment for breast cancer after menopause in Japan, as of January 31, 2016. [More...](#) (January 06, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

Development of a treatment for Eumycetoma, one of the world's most neglected diseases - The company has signed an agreement with the Drugs for Neglected Diseases initiative (DNDi) to jointly develop Eisai's azole-class antifungal drug E1224 (fosravuconazole) as a potential new treatment for eumycetoma. [More...](#) (January 08, 2016)

Fuji Pharma Company Limited ([www](#)), (Ticker: 4554)

Fuji Pharma signs license agreement for Darbepoetin Alfa, An erythropoiesis-stimulating agents - The company announced that it has signed a license agreement with Chong Kun Dang Pharmaceutical Corp. Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of Darbepoetin Alfa Biosimilar. [More...](#) (January 05, 2016)

Healios K.K. ([www](#)), (Ticker: 4593)

Announcement of collaboration between Healios and Athersys for regenerative medicine products marketed in Japan using MultiStem® cell therapy and fund borrowing by Healios - The company and Athersys, Inc. have announced a partnership and license agreement for the development of regenerative medicine products that will be developed and marketed in Japan by Healios, making use of Athersys' proprietary, patented stem cell product, MultiStem® cell therapy. [More...](#) (January 08, 2016)

Kyowa Hakko Kirin Co. Ltd ([www](#)), (Ticker: 4151)

Kyowa Hakko Kirin entered an agreement with Sandoz for exclusive marketing rights of Rituximab

biosimilar in Japan - Kyowa Hakko Kirin Co., Ltd. announced that it entered into an agreement with Sandoz KK, a Novartis company, for exclusive marketing rights to Sandoz' biosimilar Rituximab in Japan. [More...](#) (January 25, 2016)

Maruho Co., Ltd. ([www](#))

Maruho and Galderma to join forces in a strategic alliance in Japan - Maruho Co., Ltd. and Galderma Pharma S.A. announced that they have agreed to enter into a comprehensive set of agreements to form a strategic alliance focused on the development and commercialization of prescription drugs for dermatology in Japan, including therapies in the fields of acne and rosacea. [More...](#) (January 18, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda, NsGene collaborate to develop cell encapsulation therapies for Parkinson's disease -

Takeda Pharmaceutical Company Limited and NsGene, Inc. announced a research agreement to develop encapsulated cell therapies for the potential treatment of Parkinson's disease. The partnership will focus on the delivery of recombinant Glial Cell Line-Derived Neurotrophic Factor (GDNF) to affected brain regions by way of implanted, encapsulated cell therapy devices. [More...](#) (January 09, 2016)

Torii Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4551)

Aiming to contribute to psoriasis treatment in Japan, contract signed for strategic co-promotion for Ixekizumab, humanized anti-interleukin-17 monoclonal antibody - Eli Lilly Japan K.K. and Torii Pharmaceutical Co., Ltd. announced that the two companies signed a strategic sales collaboration contract in the area of dermatology in Japan for a humanized anti-interleukin-17 monoclonal antibody "Ixekizumab [recombinant], hereinafter called the Ixekizumab" that Eli Lilly Japan is developing and has filed an application for the manufacture and sale approval for the treatment of Moderate-to-Severe Plaque Psoriasis, psoriatic arthritis, pustular psoriasis, erythrodermic psoriasis last year in Japan. [More...](#) (January 08, 2016)

Court Hearing (Litigation)

Teva Pharmaceutical Industries Ltd. ([www](#))

United Therapeutics settles patent dispute with Teva Pharmaceuticals - Silver Spring-based United Therapeutics Corp. and Teva Pharmaceuticals USA Inc. have settled a dispute over Teva's plan to create a generic version of United Therapeutics' blockbuster pulmonary hypertension drug Remodulin, a Securities and Exchange Commission filing shows. [More...](#) (January 19, 2016)

Employees Related News

Asahi Kasei Corporation ([www](#)), (Ticker: 3407)

Asahi Kasei Construction Materials receives administrative dispositions in accordance with Construction Business Act - Asahi Kasei Construction Materials Corp., a subsidiary of the company received the following administrative dispositions from the Kanto Regional Development Bureau of the Ministry of Land, Infrastructure, Transport and Tourism, in accordance with Paragraphs 1 and 3 of Article 28 and Paragraph 1 of Article 41 of the Construction Business Act. [More...](#) (January 13, 2016)

Expansion/Diversification

ARKRAY Inc. ([www](#))

***Establishing an integrated manufacturing system and enhancing global competitiveness
Completion ceremony held for instrument factory and distribution center in the Philippines -***

Starting off with urine reagents, ARKRAY Industry, Inc. in the Philippines has been manufacturing in vitro diagnostic reagents since its establishment by the company as an overseas production site in September 2011. [More...](#) (January 21, 2016)

Systemex Corporation ([www](#)), (Ticker: 6869)

Medicaroid Corporation's US subsidiary commences operations in Silicon Valley - Medicaroid Corporation, a joint venture between Systemex Corporation and Kawasaki Heavy Industries, Ltd., has established a subsidiary in the United States, Medicaroid, Inc., which commenced operations in January 2016. [More...](#) (January 13, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corp sets up JV subsidiary in Malaysia - JAPAN'S Toshiba Medical Systems Corporation (TMSC) has established Toshiba Medical Systems Malaysia Sdn Bhd as a joint venture corporation with TMSC's distributor in Malaysia, Abex Medical System Sdn Bhd. [More...](#) (January 12, 2016)

Future Plans

A&D Company Ltd ([www](#)), (Ticker: 7745)

A&D Company, Limited and AtCor Medical to consider central blood pressure measurement equipment business collaboration - The company will consider business collaboration with aortic pressure measurement equipment pioneer AtCor Medical. [More...](#) (January 12, 2016)

Fujifilm Holdings Corporation ([www](#)), (Ticker: 4554)

Fujifilm to bid for Toshiba's medical equipment unit - The company plans to participate in the upcoming bidding for Toshiba Corp.'s fully owned medical equipment unit, it has been learned. [More...](#) (January 16, 2016)

Toshiba Medical Systems Corporation ([www](#))

Sony and Fujifilm Holdings mulling bids for Toshiba Medical Systems - Sony and Fujifilm Holdings are considering joining the fray to acquire a Toshiba medical equipment subsidiary, raising the prospect of a bidding war for a growth business. [More...](#) (January 06, 2016)

General

Teva Pharmaceutical Industries Ltd. ([www](#))

Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials - Teva Pharmaceutical Industries Ltd. and Active Biotech announced the discontinuation of higher doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients. [More...](#) (January 04, 2016)

Toshiba Medical Systems Corporation ([www](#))

Toshiba Medical Systems Corporation to bring leading-edge medical diagnostic imaging systems to Arab health 2016 - Toshiba Medical Systems Corporation (TMSC) announced that it will exhibit its

latest diagnostic imaging systems at Arab Health 2016, the world's largest exhibition of medical equipment, which will be held at the Dubai International Convention & Exhibition Centre from January 25 to 28. [More...](#) (January 18, 2016)

Investments

Topcon Corporation ([www](#)), (Ticker: 7732)

Topcon invests in Viasys VDC - Topcon Positioning Group announces that it has acquired a significant share of holdings in Viasys VDC, based in Espoo, Finland. [More...](#) (January 12, 2016)

Toshiba Medical Systems Corporation ([www](#))

Inviting outside investment in the business based on "Toshiba Revitalization Action Plan" -

Toshiba Medical Systems Corporation has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of "Toshiba Revitalization Action Plan" by Toshiba Corporation. [More...](#) (January 18, 2016)

Joint Ventures

Otsuka Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4578)

Otsuka Pharmaceutical enters into comprehensive health promotion partnership with Iwate Prefecture -

Otsuka Pharmaceutical has entered into a Comprehensive health promotion partnership with Iwate Prefecture as part of the Healthy Iwate 21 Plan to promote healthy longevity and improve the quality of life for prefectural citizens. [More...](#) (January 13, 2016)

Sysmex Corporation ([www](#)), (Ticker: 6869)

Sysmex enters business alliance agreement with Eiken Chemical Co., Ltd., involving the urine chemistry testing business in overseas markets -

Sysmex Corporation has entered a business alliance with Eiken Chemical Co. Ltd. involving the urine chemistry testing business in overseas markets. Going forward, the two companies aim to collaborate to become frontrunners in the urinalysis field. [More...](#) (January 08, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) -

Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. [More...](#) (January 22, 2016)

Takeda and enGene establish strategic alliance to develop novel therapeutics for gastrointestinal diseases -

Takeda Pharmaceutical Company Ltd. and enGene, Inc. announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGene's "Gene Pill" gene delivery platform. [More...](#) (January 12, 2016)

Mergers and Acquisitions

Hitachi Aloka Medical, Ltd. ([www](#))

Hitachi announces changes in the method of the reorganization of Hitachi Medical and Hitachi Aloka Medical and the execution of absorption-type company split agreement - Hitachi Ltd, Hitachi Medical Corporation and the company announced that a decision has been made regarding the absorption type merger of Hitachi Medical and the company by Hitachi and the establishment of a manufacturing subsidiary as part of efforts to strengthen the health care business. [More...](#) (January 13, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda acquires U.S. biologics manufacturing facility - Takeda Pharmaceutical Company Limited announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc. Takeda intends to use the facility primarily for the manufacture of Entyvio® and other biologic products, allowing the company to maximize global efficiencies and further enhance the product's supply chain flexibility. [More...](#) (January 06, 2016)

New Products

Kissei Pharmaceutical Company Limited ([www](#)), (Ticker: 4547)

Announcement of the launch of Urief® OD Tab. (orally disintegrating tablets) for the treatment of dysuria associated with benign prostatic hyperplasia in Japan - Kissei Pharmaceutical Co., Ltd. announced that they will launch Urief® OD Tab. 2mg and Urief® OD Tab. 4mg (generic name: silodosin, hereinafter referred to as the "drug") for the treatment of dysuria associated with benign prostatic hyperplasia on January 18. [More...](#) (January 15, 2016)

Ohara Inc ([www](#)), (Ticker: 5218)

Ultra-Low expansion glass ceramics which was adopted for the world's largest telescope~ production upgrade of CLEARCERAM™-Z - Ohara Incorporation has built another large furnace for ultra low expansion glass ceramics, CLEARCERAM™-Z, for stable supply and further increase in demand. [More...](#) (January 13, 2016)

Shimadzu Corporation ([www](#)), (Ticker: 7701)

Shimadzu releases the Xslicer SMX-6000 microfocus X-Ray inspection system the first system from Shimadzu to integrate inclined fluoroscopy and CT imaging into a single package - Shimadzu Corporation announces the release of the Xslicer SMX-6000 microfocus X-ray inspection system for non-destructive inspections. This is the first Shimadzu system to include inclined fluoroscopy and CT imaging functionalities in a single package and which is capable of obtaining cross-sectional images immediately after inclined fluoroscopy. [More...](#) (January 07, 2016)

Sysmex Corporation ([www](#)), (Ticker: 6869)

Sysmex launches the UC-3500 Fully-Automated Urine Chemistry Analyzer, its First Product in the Field of Urine Qualitative Analysis in Overseas Markets - Sysmex Corporation is launching the UC-3500 fully-automated urine chemistry analyzer, its first urine qualitative analyzer under its own brand to overseas markets, based on a business alliance with Eiken Chemical Co. Ltd. [More...](#) (January 08, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Launch of the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape - Taisho

Pharmaceutical Holdings Co., Ltd. has announced that its consolidated subsidiary Taisho Pharmaceutical Co., Ltd. has decided to launch on January 21 the transdermal anti-inflammatory analgesic patch formulation LOQOA® Tape (generic names: S-flurbiprofen, mentha oil) for the indication and usage of "the treatment of osteoarthritis pain and inflammation." [More...](#) (January 20, 2016)

Yamato Scientific Co. Ltd. ([www](#))

New Product Information: IL603 / ILE800 - The company is pleased to announce the launch of our newly upgraded Incubator (Model: IL603/ILE800). These models are equipped with a newly developed "Refrigerator Circuit" which enables the evaporator to be less affected by frost forming (Patent Pending). [More...](#) (January 20, 2016)

Patent/Trademark/License/Approval

3 D Matrix Ltd ([www](#)), (Ticker: 7777)

3-D Matrix announces Absorbable Hemostat PuraStat® Product Registration Obtained in Thailand - The company said that its subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Thailand has been granted by the regulatory body, Food and Drug Administration Thailand (FDA Thailand). [More...](#) (January 25, 2016)

Absorbable Hemostat PuraStat® product registration obtained in Australia - The 3-D Matrix group is working towards commercialization of absorbable hemostat PuraStat® globally. The company announced that the subsidiary, 3-D Matrix Asia Pte. Lt. (3DMA), has received notification that the medical device product registration approval in Australia has been granted by the Australian regulatory body, Therapeutic Goods Administration (TGA). [More...](#) (January 22, 2016)

Patent granted on "3-D Cell Culture Scaffold" in Canada with self-assembling peptide technology exclusively licensed by MIT - In regards to a self-assembling peptide technology that the company has exclusive licensing rights from the Massachusetts Institute of Technology, the company announced that a patent filed by MIT, the licensor, related to bone / cartilage regeneration and skin regeneration fields in which developments are in progress was granted in Canada. [More...](#) (January 05, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Repatha® (Evolocumab) approved as first PCSK9 inhibitor in Japan for the treatment of high cholesterol - Amgen Astellas BioPharma K.K. and the company announced that Amgen Astellas received approval for the cholesterol-lowering medication Repatha® (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in Japan from the Japanese Ministry of Health, Labour and Welfare. [More...](#) (January 22, 2016)

Chugai Pharmaceutical Co. Ltd. ([www](#)), (Ticker: 4519)

Chugai Pharma receives Japanese approval for osteoporosis drug, Bonviva tablet - The company and Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of Bonviva tablet 100mg (ibandronate sodium hydrate tablet), a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. (Roche) and, in Japan, by Chugai co-developed with Taisho, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 23, 2016)

Eisai Co. Limited ([www](#)), (Ticker: 4523)

U.S. FDA accepts for priority review sNDA for Eisai's anticancer agent lenvatinib seeking approval

for renal cell carcinoma - The company announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) submitted by its U.S. subsidiary Eisai Inc. for Eisai's in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma, and granted the sNDA Priority Review status. [More...](#) (January 18, 2016)

Eisai submits new application in Europe for in-house developed anticancer agent lenvatinib seeking approval for indication covering renal cell carcinoma - The company announced that its European regional headquarters Eisai Europe Ltd. has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate (generic name, "lenvatinib") for use in the treatment of advanced or metastatic renal cell carcinoma. [More...](#) (January 12, 2016)

Japan Life Company Limited ([www](#)), (Ticker: 7575)

Announcement of regulatory approval for the atrial septal defect (ASD) occluder "Figulla Flex II" - Japan Lifeline announced that, on January 5, the company had received regulatory approval for the ASD Occluder "Figulla Flex II" manufactured by Occlutech (Switzerland). The sales launch is scheduled on February 1, 2016. [More...](#) (January 12, 2016)

Nippon Shinyaku Co., Ltd. ([www](#)), (Ticker: 4516)

Nippon Shinyaku submits NDA to MHLW for Selexipag for treatment of pulmonary arterial hypertension. - Nippon Shinyaku Co., Ltd. announced the submission of the New Drug Application (NDA) for selexipag which was originally discovered and synthesized by Nippon Shinyaku Co., Ltd. and was jointly developed in Japan with Actelion Pharmaceuticals Japan Ltd., to the Ministry of Health, Labor and Welfare (MHLW) for the treatment of pulmonary arterial hypertension (PAH). [More...](#) (January 07, 2016)

Olympus Corporation ([www](#))

Olympus receives 510(k) clearance for TJF-Q180V Duodenoscope - Olympus announced that FDA has cleared the 510(k) for the TJF-Q180V duodenoscope with modifications to the device design and labeling. The duodenoscope is a flexible gastrointestinal endoscope used in procedures such as endoscopic retrograde cholangiopancreatography (ERCP), which is most commonly performed to diagnose and treat conditions in the pancreas, bile duct and gallbladder. [More...](#) (January 15, 2016)

Ono Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4528)

FDA approves new Kyprolis® (Carfilzomib) combination therapy for the treatment of patients with relapsed or refractory multiple myeloma - Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. [More...](#) (January 22, 2016)

ONO submits manufacturing and marketing approval application in Japan for "Etelcalcetide Hydrochloride" (ONO-5163), a calcimimetic agent, for secondary hyperparathyroidism in patients on hemodialysis - ONO PHARMACEUTICAL CO., LTD. announced the submission of Manufacturing and Marketing Approval Application in Japan for "etelcalcetide hydrochloride" (ONO-5163), a calcimimetic agent, to seek an indication for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. [More...](#) (January 14, 2016)

Otsuka Pharmaceutical Co., Ltd. ([www](#)), (Ticker: 4578)

Otsuka and ARIAD announce new drug application for ponatinib submitted in Japan for the treatment of refractory leukemia - Ponatinib (generic name) is a tyrosine kinase inhibitor discovered by ARIAD Pharmaceuticals in the United States. The New Drug Application (NDA) for ponatinib was filed in Japan for the first time as a novel oral treatment for chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). [More...](#) (January 08, 2016)

Taisho Pharmaceutical Holdings Co., Ltd. ([www](#)), (Ticker: 4581)

Agent for Osteoporosis approved in Japan "Bonviva® Tablet" - Taisho Pharmaceutical Co., Ltd. announced that Chugai obtained approval of ibandronate sodium hydrate tablet [brand name: Bonviva® Tablet 100mg (Bonviva Tablet)], a bisphosphonate antiresorptive agent which was developed by F. Hoffmann-La Roche, Ltd. and, in Japan, by Taisho co-developed with Chugai, from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the osteoporosis indication. [More...](#) (January 22, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda announces new drug application approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib®" - Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application ("NDA") for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. [More...](#) (January 22, 2016)

European Commission approves label variation for ADCETRIS® (Brentuximab Vedotin) to include data on retreatment of adult patients with relapsed or refractory hodgkin lymphoma and systemic anaplastic large cell lymphoma - Takeda Pharmaceutical Company Limited announced that the European Commission (EC) has approved a Type II variation for ADCETRIS® (brentuximab vedotin) to include data on the retreatment of adult patients with relapsed or refractory (R/R) Hodgkin lymphoma or R/R systemic anaplastic large cell lymphoma (sALCL) who previously responded to ADCETRIS and who later relapse. The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in October 2015. [More...](#) (January 22, 2016)

Research & Development**AnGes MG, Inc.** ([www](#)), (Ticker: 4563)

Anges MG : completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan - The company has announced the completion of patient enrollment in the phase III clinical trials of NF-kB decoy oligonucleotide ointment drug for atopic dermatitis in Japan. [More...](#) (January 19, 2016)

Astellas Pharma Inc. ([www](#)), (Ticker: 4503)

Astellas, Medivation report successful enzalutamide mCRPC Phil data in Lancet - The U.S. arm of the company and U.S.-listed Medivation said that enzalutamide met its primary endpoint in a Phase II study to treat metastatic castration-resistant prostate cancer (mCRPC). [More...](#) (January 14, 2016)

Daiichi Sankyo Company Limited ([www](#)), (Ticker: 4568)

Daiichi Sankyo announces results of phase 3 international joint trial (RApsody) of Investigational Etanercept Biosimilar - The company announced that they have achieved major objectives in the Phase 3 international joint trial (RApsody) of CHS-0214, an investigational etanercept (genetical recombination) biosimilar*1 in rheumatoid arthritis (RA) under development with the U.S. company, Coherus

BioSciences, Inc. (hereinafter, Coherus). [More...](#) (January 12, 2016)

OncoTherapy Science, Inc. ([www](#)), (Ticker: 4564)

The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA - OncoTherapy Science, Inc. announces that we will conduct Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA). [More...](#) (January 25, 2016)

MELK inhibitor, OTS167, Phase I clinical study commencement in Australia - OncoTherapy Science, Inc announces that the Human Research Ethics Committee (HRECs) at the trial site in Australia has approved the commencement of Phase I clinical study of MELK inhibitor, OTS167. [More...](#) (January 05, 2016)

Takeda Pharmaceutical Company Ltd ([www](#)), (Ticker: 4502)

Takeda and Enterome enter strategic drug discovery collaboration focused on microbiome targets across multiple gastrointestinal disorders - Takeda Pharmaceutical Company Ltd. and Enterome Bioscience SA announced that they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases and motility disorders. [More...](#) (January 06, 2016)

Sale/Purchase of Company Stakes

Acucela Inc. ([www](#)), (Ticker: 4589)

Kubota Ryo reduced position in Acucela Inc - Mr. Kubota Ryo has filled a SC 13D/A form regarding the company. As per Mr. Kubota Ryo's filing, the filler reported decreased stake in the company by -75.63 % to 10,250,654 shares. [More...](#) (January 22, 2016)

[Top](#)**SECTION B : STOCK PRICE CHANGES****Stock Analysis - Top Gainers and Decliners in Japan Life Science Sector**

Country	Company	Stock Price Jan 25, 2016	Stock Price Jan 01, 2016	Current Month % Chg
Top Gainers				
Japan	GreenPeptide (4594)	400	270	48.15
Japan	Acucela (4589)	1086	863	25.84
Japan	Techno Horizon Holdings Co Limited (6629)	277	226	22.57
Japan	Medical Data Vision Co Ltd (3902)	2062	1763	16.96
Japan	Nikon Corporation (7731)	1745	1598	9.2
Japan	Aisei Pharmacy Co., Ltd (3170)	4080	3805	7.23
Japan	Eiken Chemical Co., Ltd. (4549)	2266	2143	5.74
Japan	Umn Pharma Inc (4585)	1850	1752	5.59
Japan	Kawasumi Laboratories, Incorporated (7703)	919	880	4.43
Japan	Yakuodo Company Limited (3385)	2916	2872	1.53
Top Decliners				
Japan	Ribomic (4591)	673	1255	-46.37
Japan	Nihon ISK Co Ltd (7986)	144	200	-28
Japan	I'rom Group Co Ltd (2372)	830	1132	-26.68
Japan	Dream Incubator Incorporated (4310)	2028	2750	-26.25
Japan	Symbio Pharmaceuticals Ltd (4582)	181	244	-25.82
Japan	Okamoto Glass Co., Ltd. (7746)	158	212	-25.47
Japan	Atect Corp (4241)	742	989	-24.97
Japan	Yamane Medical Corp (2144)	200	263	-23.95
Japan	GNI Group Ltd. (2160)	136	177	-23.16
Japan	Oncolys Biopharma Inc (4588)	493	639	-22.85

[Top](#)**SECTION C : FINANCIAL PERFORMANCE OF JAPAN LIFE SCIENCE SECTOR****C-1 Fastest Growing**

Company	Ticker	Sub-Industry	Overall Rank	Sales Growth Rank	Sales Growth %	Assets Growth Rank	Assets Growth %
Imageone Company Ltd.	2667	M-D/T/S	1	4	225.74	3	26.70
Tsuruha Company, Ltd.	3391	P	2	10	96.62	7	12.48
Ad Me Tech	7778	M-D/T/S	3	7	125.00	16	6.78
Techno Medica Co., Ltd.	6678	M-D/T/S	4	12	65.94	12	9.12
Welcia Holdings Co.Limited	3141	P	5	28	23.03	2	30.73

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-2 Most Profitable

Company	Ticker	Sub-Industry	Overall Rank	Net Income/Total Sales		Net Income/Total Assets		Net Income/Total Equity	
				Rank	Ratio	Rank	Ratio	Rank	Ratio
Santen Pharmaceutical Co., Ltd.	4536	P	1	1	72.38	1	10.26	1	14.40
Asahi Intecc Co., Ltd.	7747	M-D/T/S	2	3	22.85	2	5.03	3	7.95
Kaken Pharmaceutical Co., Ltd.	4521	P	3	4	22.62	3	4.97	5	7.23
Hoya Corporation	7741	M-D/T/S	4	5	20.11	5	3.78	12	4.72
M3 Inc	2413	HS	5	13	17.18	4	4.05	8	5.29

Note: For the sub-industry column above, HS = Health Services, M-D/T/S = Medical Devices/Technology/Supplies, and P = Pharmaceuticals

C-3 Most Efficient

Company	Ticker	Sub-Industry	Overall Rank	Total Sales/Total Assets		Total Sales/Total Equity	
				Rank	Ratio	Rank	Ratio
Kawanishi Holdings Incorporated	2689	M-D/T/S	1	6	0.75	1	5.19
Medius Holdings Company Limited	3154	M-D/T/S	2	8	0.72	3	4.44
Chuo Bussan Corporation	9852	P	3	4	0.79	8	2.27
Tsuruha Company, Ltd.	3391	P	4	3	0.86	12	1.88
Yamashita Medical Instruments Company Limited	3022	M-D/T/S	5	7	0.74	10	1.98

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-4 Most Improved

Company	Ticker	Sub - Industry	Sales Growth (Q3-Q2) %	Sales Growth (Q2-Q1) %
Data Horizon Co Ltd	3628	M-D/T/S	55.17	-71.79
Imageone Company Ltd.	2667	M-D/T/S	225.74	-76.35
Jeol Limited	6951	M-D/T/S	55.79	-49.42
Techno Medica Co., Ltd.	6678	M-D/T/S	65.94	-57.55
Trans Genic	2342	B	44.71	-61.54

Note: For the sub-industry column above, B = Biotech and M-D/T/S = Medical Devices/Technology/Supplies

C-5 Multinational Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	Foreign Sales Current Year		Foreign Sales to Total Sales %		Foreign Sales Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Sysmex Corporation	6869	M-D/T/S	1	11	1208.57	4	78.15	4	17.02
Otsuka Holdings Company Limited	4578	P	2	3	6908.82	11	56.75	7	13.21
Astellas Pharma Inc.	4503	P	3	4	6359.55	7	60.85	15	5.04
Terumo Corporation	4543	M-D/T/S	4	9	2332.30	8	59.55	10	9.99
Canon Electronics Inc.	7739	M-D/T/S	5	1	25164.60	2	80.57	28	14.85

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

C-6 Research-Intensive Life Science Companies

Company	Ticker	Sub-Industry	Overall Rank	R&D Exp Current Year		R&D Exp to Total Sales %		R&D Exp Growth %	
				Rank	Amount (in USDm)	Rank	Percent	Rank	Ratio
Ad Me Tech	7778	M-D/T/S	1	9	213.48	3	155.34	1	103.59
Kissei Pharmaceutical Co., Ltd.	4547	P	2	13	121.41	8	20.66	13	9.64
Daiichi Sankyo Company Limited	4568	P	3	3	1597.78	7	20.74	38	-9.76
Astellas Pharma Inc.	4503	P	4	2	1731.26	13	16.56	35	-7.73
Cyberdyne Inc	7779	M-D/T/S	5	48	8.24	2	155.76	10	17.40

Note: For the sub-industry column above, M-D/T/S = Medical Devices/Technology/Supplies and P = Pharmaceuticals

Published by: FinGlobe Inc., **Address:** 5 Independence Way, Suite 300 Princeton, NJ 08540 USA

Phone: 1-609 514 5140 **Fax:** 1-609 514 5104

www: www.finglobedirect.com **Email:** info@finglobedirect.com

To subscribe, please visit <http://finglobedirect.com/index.php/japan-life-sciences-business-monthly>

For other publications on Japan Life Sciences Sector, please visit:

<http://finglobedirect.com/index.php/japan-life-sciences>

For our publications on global life sciences sectors, please visit finglobedirect.com.



Please follow us on:

For Japan Life Sciences companies and international companies with activities in Japan's Life Sciences sector, please send news and financial reports to: info@finglobedirect.com Thank you.

Disclaimer: *Japan Life Sciences Monthly is based on public domain information believed to be reliable, but no warranties are provided.*

Copyright © 2016 FinGlobe, Inc. USA